About 1734 shares advanced, 1817 shares declined, and 133 shares unchanged.
Divi's Lab net profit increased by 78 per cent to Rs 895 crore in the March quarter against Rs 502 crore a year ago. Revenue from operations rose 40% to Rs 2,518 crore as against Rs 1,788 crore in the year-ago period.
With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?
Net Sales are expected to increase by 20.9 percent Y-o-Y (down 1.3 percent Q-o-Q) to Rs. 1,680 crore, according to Sharekhan.
Net Sales are expected to increase by 5.4 percent Y-o-Y (up 16.5 percent Q-o-Q) to Rs. 1,354.7 crore, according to Emkay.
Net Sales are expected to increase by 25 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 1,297.4 crore, according to Sharekhan.
Net Sales are expected to increase by 20 percent Y-o-Y (up 7.3 percent Q-o-Q) to Rs. 1,068.2 crore, according to Sharekhan.
The company that earlier maintained a clean regulatory track record failed spectacularly in the US FDA's audit last December.
Markets slipped in trade today erasing all the gains made so far in 2016. The Nifty is now negative for 2016 erasing all gains made so far this year and also ending at its lowest level in 2016. Midcaps got battered in trade.
ACC | Ambuja Cement | India Cements | IOC | MCX | Ramco Cements | UltraTech Cement | Jaiprakash Associates | JK Cements | Tata Power | KEC International | Uniply Industries | C&C Constructions | Praj Industries | Esab India and Indo Rama Synthetics are stocks, which are in the news today.
In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.